As a result of the increased spread of the Corona virus and due to the Public Health Agency’s now changed assessment of the risk level for the spread of the virus – an increase in risk level to “Very High risk” we have decided to postpone our planned seminar: Optimizing the path to market for ATMP’s.
We hope to reschedule the seminar later in the year and we will provide you all with more information closer to the time.
If you would like to talk to one of our team about how we can support, you and your teams drug development program please do not hesitate to contact us.
NDA Group & Cirio Advokatbyrå
Our presenters will discuss integrated product development for ATMPs to meet regulatory and HTA requirements and models for realizing product value.
Date: Tuesday 31st of March 2020 – Postponed
Time: 08:30- 11:30 (Breakfast served at 08:30, seminar starts at 09:00)
Venue: Cirio Advokatbyrå, Mäster Samuelsgatan 20, 8th floor, Stockholm
Registration: RSVP by Friday 27th March 2020
This seminar is focused on the challenges of ATMP development and market access with case examples of approved products. The option of an integrated product development to cover both regulatory and HTA expectations will be presented, together with information on regulatory, HTA and market access support available for ATMP developers
Our speakers for the day:
- Paula Salmikangas, Director of Biopharmaceuticals and ATMP, NDA Group
- Ben Continsouzas: Senior Consultant, Project Manager at NDA Advisory Service
- Per Hedman, Partner, Cirio Law firm
- Anders Burén, Senior Counsel, Cirio Law firm